David McCullough

Katherine Wolf

Denise Barbut

Michael Zasloff

William Kinney

Hilde Williams

David McCullough

CEO and Board Member

With over 30 years of pharma/biotech experience, Mr. McCullough is a demonstrated strategic, creative, and accomplished leader. With executive and board director experience in startup and established companies, David brings expertise in both the private and public sector. He has a deep understanding of drug development, clinical and regulatory strategy, commercial, finance, IP, manufacturing and operations. Mr. McCullough has a proven track record of building highly skilled, energetic, cross-functional teams both domestically and globally. He has strong experience moving products from early development to launch, including orphan drugs and billion-dollar brands. At Merck, he played a lead role in the $13.5B acquisition of Serono Biotech, and he was honored by the Merck family as a top contributor in corporate development. Additionally, Mr. McCullough has held leadership positions in Allergopharma/EMD Serono and BioCryst. He is interested in Enterin as he has a personal passion for the neurodegenerative therapeutic area and the patient population that can be served with better therapeutic outcomes.

Katherine Wolf

Chief Financial Officer

Ms. Wolf brings 30 years of health care industry experience in capital raising, business development, and strategy, during which she has executed financing, advisory, and M&A transactions worth approximately $24 billion. She has deep experience as a healthcare CFO, advisor, and investment banker. Her background in capital markets, her reputation among the financial community, and her experience as a public company CFO will help Enterin position the company for the the next phase of growth.

Before joining Enterin, Ms. Wolf was Managing Member of health care consultancy KLW Advisors where she worked as an advisor and Acting CFO to various clients, prior to which she served as Partner and Senior Advisor at Ondra Partners, a boutique investment bank. Previously, her positions included CEO & Co-Founder of health care consultancy Rocket Science, and CFO & EVP of Vision-Sciences, a publicly traded medical technology company. Additionally, Ms. Wolf has extensive prior health care investment banking experience at both global and boutique investment banks, including HSBC Securities, Bear Stearns and SG Cowen. Ms. Wolf received an MBA from Harvard Business School and a BA from Williams College.

Denise Barbut, MD, FRCP

Co-Founder, President, CMO, and Board Member

Dr. Barbut is a Professor of Neurology & Former Chief of the Neurovascular Division and of the Stroke research Program at Weill-Cornell Medical College. She trained as an internist and subsequently as a neurologist in Great Britain and the USA. She received her Medical Degree from University College, London. She completed her post-graduate training at Imperial College, the Royal Brompton Hospital and the National Hospital for Neurology and Neurosurgery, Queens’ Square. She is a Fellow of the Royal College of Physicians of the United Kingdom. She completed her neurologic training at Weill-Cornell Medical Center- Cornell University Medical College and Memorial Sloan-Kettering Cancer Center. Subsequently she became an Attending Physician at New York Hospital and Professor of Neurology at Cornell University.

She holds close to 200 patents, relating to methods for neuroprotection, cerebral hypothermia, the treatment of cerebral ischemia, pain, neuromodulation, Parkinson’s disease and other neurodegenerative disorders and has published close to 60 peer-reviewed articles. She has previously founded and led biotech companies to develop novel treatments in the field of neurology. Her current research interests are focused on the role of aminosterols in the treatment of neurodegenerative diseases. She co-founded Enterin with Michael Zasloff in 2016, and currently serves as President, CMO, and Board Member.

Michael Zasloff, MD, PhD

Co-Founder, CSO, and Board Member

Dr. Zasloff is a Professor of Pediatrics and Genetics at Georgetown University and the former Dean of Research and Translational Science at Georgetown University. Over the past 25 years, Dr. Zasloff’s scientific interests have centered on the innate immune systems of animals. Dr. Zasloff received his M.D.-Ph.D. in the Medical Scientist Training Program at New York University School of Medicine.

In the 1980’s, Dr. Zasloff was Chief, Human Genetics Branch, National Institutes of Child Health and Human Development, at the National Institutes of Health. He founded Magainin Pharmaceuticals, Inc. a publicly traded biotechnology company. He joined the faculty of the University of Pennsylvania School of Medicine as the Charles E. H. Upham Professor of Pediatrics and Genetics and assumed the position of Director of the Division of Human Genetics of the Children’s Hospital of Philadelphia.  In 1992, Dr. Zasloff left U. Penn and joined Magainin on a full-time basis and served as Chairman of the Board, Executive Vice President and President of the Magainin Research Institute, a basic research division of the Company. In 2002, Dr. Zasloff was named Dean of Research and Translational Science at Georgetown, tasked with the integration of the basic science conducted at Georgetown with the clinical environment of the Medical Center. Since 2004, Dr. Zasloff has been actively engaged in studies of innate immunity as Scientific Director of the MedStar-Georgetown Transplant Institute.

His research interests remain focused on the role of antimicrobial peptides and aminosterols in health and disease, and application to the prevention and treatment of disease. He has published over 150 peer-reviewed articles and holds over 60 issued US patents. He co-founded Enterin in 2016 with Denise Barbut and currently serves as CSO and Board Member. He also serves as the lead independent Director on the Board of Amphastar Pharmaceuticals, Inc. He has received numerous awards including an honorary Doctor of Science from Georgetown University in 2011.

William Kinney, PhD

Co-Founder, Senior VP, Research & Development

Dr. Kinney is a drug discovery scientist, process development chemist, and entrepreneur with greater than 30 years of experience in large pharmaceutical (Wyeth, Johnson & Johnson), biotechnology (Magainin), and non-profit (Blumberg Institute) research and development.

He has demonstrated expertise in drug design; synthesis; lead optimization of peptides, small molecules, natural products, and cGMP drug development; and is inventor of three molecules that advanced to human clinical trials – Perzinfotel (CNS disorders and pain), Squalamine (oncology and AMD), and Trodusquemine (obesity).  He was the chemistry leader on the initial squalamine IND project team, delivering drug substance to launch a Phase I clinical trial on time and on budget. The squalamine cGMP scale-up campaign required building and leading an internal process group, partnering with analytical chemistry on method development and stability studies, working with multiple domestic and international collaborators, and writing the CMC section of the IND.

In 2000, he joined Johnson & Johnson, where he pursued peptide-mimetic integrin antagonists and urotensin-II receptor modulators for cardiovascular indications.  He also made seminal discoveries with respect to self-assembling collagen-mimetic peptides that stimulate platelet aggregation.

Currently, Dr. Kinney is co-founder and Vice President of Research and Development at Enterin, Inc. where he leads scale-up of drug substance and drug product for the ENT-01 IND for the treatment of Parkinson’s Disease.  His scientific contributions include 80 publications, invited lectures, and oral presentations and inventorship on 42 issued U.S. patents.

Hilde Williams

Senior Regulatory Advisor, Regulatory Strategy and Operations

With over 30 years’ in the biotechnology/pharmaceutical industry, Hilde is an expert in strategic regulatory affairs and clinical development across multiple disease areas and compound classes. Hilde’s deep regulatory affairs expertise has focused on investigational pharmaceutical products, including Phase I through Phase IV development. Hilde served as Sr. Vice President, Regulatory Affairs and Development, Acadia Pharmaceuticals where she oversaw the only successful Phase 3 program in Parkinson’s Disease Psychosis. Hilde garnered FDA agreement for an NDA submission based on a single study, gained strategic Breakthrough Designation (first for FDA Psychiatry Division) and oversaw development of a high-quality NDA granted Priority Review by the FDA, and subsequent approval. During her career, Hilde has provided leadership on regulatory and development activities associated with the launch and conduct of five other development programs for CNS and psychiatric indications.